Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine

Bibliography

• Adema AD, Bijnsdorp IV, Sandvold ML, Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem 2009;16:4632-43
   PubMed Web of Science ®Google Scholar
• Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003;8:553-66
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HHJ, Freemantle S, Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205
   PubMed Web of Science ®Google Scholar
• Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5:19-33
   PubMed Web of Science ®Google Scholar
• Adema AD, Losekoot N, Smid K, Differential metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 2011; In press
   Web of Science ®Google Scholar
• Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31
   PubMed Web of Science ®Google Scholar
• Heinemann V, Xu YZ, Chubb S, Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-72
   PubMed Web of Science ®Google Scholar
• Mackey JR, Mani RS, Selner M, Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-57
   PubMed Web of Science ®Google Scholar
• Heinemann V, Xu YZ, Chubb S, Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-9
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen V, Veerman G, Vermorken JB, Peters GJ. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993;46:762-6
   PubMed Web of Science ®Google Scholar
• Ruiz van Haperen VW, Veerman G, Boven E, Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994;48:1327-39
   PubMed Web of Science ®Google Scholar
• Honeywell R, Giovannetti E, Peters GJ. Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. Nucleosides Nucleotides Nucleic Acids 2011;30:1203-13
   PubMed Web of Science ®Google Scholar
• Huang P, Chubb S, Hertel LW, Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-17
   PubMed Web of Science ®Google Scholar
• Peters GJ, Van Moorsel CJ, Lakerveld B, Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 2006;28:237-44
   PubMed Web of Science ®Google Scholar
• Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005;10:34-51
   PubMed Web of Science ®Google Scholar
• Tempero M, Plunkett W, Ruiz van Haperen V, Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-8
   PubMed Web of Science ®Google Scholar
• Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008;109(3):329-34
   PubMed Web of Science ®Google Scholar
• Poplin E, Feng Y, Berlin J, Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778-85
   PubMed Web of Science ®Google Scholar
• Grimison P, Galletis P, Manners S, Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation. J Clin Oncol 2007;36:5704-9
   Web of Science ®Google Scholar
• De Lange SM, Van der Born K, Kroep JR, No evidence of gemcitabine accumulation during weekly administration. Eur J Clin Pharmacol 2005;61:843-9
   PubMed Web of Science ®Google Scholar
• Veerman G, Ruiz van Haperen VWT, Vermorken JB, Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-42
   PubMed Web of Science ®Google Scholar
• van Riel JM, Peters GJ, Mammatas LH, A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur J Cancer 2009;45:2519-27
   PubMed Web of Science ®Google Scholar
• Witjes JA, Van der Heijden AG, Vriesema JLJ, Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004;45:182-6
   PubMed Web of Science ®Google Scholar
• Morgan RJ Jr, Synold TW, Xi B, Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 2007;13:1232-7
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Aghajanian C, Leitao M, Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 2004;10:2962-7
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Funel N, Peters GJ, MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70:4528-38
   PubMed Web of Science ®Google Scholar
• Voortman J, Goto A, Mendiboure J, Small cell lung carcinoma − resection of non treated with adjuvant chemotherapy after complete MicroRNA. Cancer Res 2010;70:8288-98
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Mercier C, Dahan L, Andre N. Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 2011;8:439-44
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Finkler NJ, Rutherford T, OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011;29:abstract LBA5007
   Google Scholar
• Bolis G, Scarfone G, Giardina G, Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001;81:3-9
   PubMed Web of Science ®Google Scholar
• Cantu MG, Buda A, Parma G, Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002;20(5):1232-7
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28(20):3323-9
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28(19):3107-14
   PubMed Web of Science ®Google Scholar
• van Moorsel CJ, Kroep JR, Pinedo HM, Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999;10:441-8
   PubMed Web of Science ®Google Scholar
• Nagourney RA, Brewer CA, Radecki S, Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88(1):35-9
   PubMed Web of Science ®Google Scholar
• Bergman AM, Kuiper CM, Voorn DA, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004;67:503-11
   PubMed Web of Science ®Google Scholar
• Rizzieri D, Vey N, Schlenck N, A phase II study of elacytarabine/idarubicin as second course remission-induction in patients with acute myeloid leukemia who failed cytarabine/anthracycline, and evaluation of the impact of the nucleoside transporter hENT1 on response. Blood Proc ASH 2011;abstract #42825
   Google Scholar
• Sigmond J, Kamphuis JA, Laan AC, The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem Pharmacol 2007;73:1548-57
   PubMed Web of Science ®Google Scholar
• Yen Y, Chow W, Leong L, Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemother Pharmacol 2002;50(5):353-9
   PubMed Web of Science ®Google Scholar
• Traynor AM, Lee JW, Bayer GK, A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: eastern Cooperative Oncology Group Study 1503. Invest New Drugs 2010;28:91-7
   PubMed Web of Science ®Google Scholar
• Muggia FM, Hazarika M. Ovarian cancer: rationale and strategies beyond first-line treatment. In: Angioli R, Kavanagh JJ, Pecorelli S, Penalver M, editors. Chemotherapy for Gynecological Neoplasms: Current Therapy and Novel Approaches. Marcel Dekker; New York: 2004. p. 471-82
   Google Scholar
• Arlt A, Gehrz A, Muerkoster S, Role of NF-kappaB and Akt/P13K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51
   Google Scholar